Journals / Turkish Journal of Gastroenterology / 2009 / Cilt: 20 - Sayı: 1

İnflamatuvar barsak hastalığı aktivitesinin belirlenmesinde serum prokalsitonin seviyesinin önemi

Diagnostic value of serum procalcitonin in determining the activity of inflammatory bowel disease

Pages
9–12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Procalcitonin has no diagnostic value in determining disease activity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: Procalcitonin and C-reactive protein are two acute-phase reactant proteins, although procalcitonin is a more specific marker for bacterial infections.
📊
Key Findings & Data:Disease activity, white blood cell count, sedimentation rate, serum procalcitonin and C-reactive protein levels were evaluated in 45 newly diagnosed inflammatory bowel disease patients (9 Crohn’s disease and 36 ulcerative colitis).
💡
Conclusion & Impact:Procalcitonin has no diagnostic value in determining disease activity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kolit · ülseratif · Crohn hastalığı

Abstract

Background/aims: Procalcitonin and C-reactive protein are two acute-phase reactant proteins, although procalcitonin is a more specific marker for bacterial infections. Procalcitonin level might also be helpful to predict the disease activity of inflammatory bowel disease. This study aimed to compare the diagnostic value of serum procalcitonin and C-reactive protein as indicators of disease activity in inflammatory bowel disease. Methods: Patients admitted to the inflammatory bowel disease inpatient clinic with suspected inflammatory bowel disease who had not yet been treated with immunosuppressive treatments were included. Disease activity, white blood cell count, sedimentation rate, serum procalcitonin and C-reactive protein levels were evaluated in 45 newly diagnosed inflammatory bowel disease patients (9 Crohn&#8217;s disease and 36 ulcerative colitis). Fifty healthy volunteers were analyzed as a control group. Results: Crohn&#8217;s disease patients had higher procalcitonin and C-reactive protein levels than healthy controls (Procalcitonin: 0.143±0.081 vs. 0.065±0.008 ng/ml, p<0.05; C-reactive protein: 29±7.5 vs. 2.9±0.5 mg/dl, p<0.001, respectively). Ulcerative colitis patients also had slightly higher procalcitonin levels and significantly higher C-reactive protein levels than controls (Procalcitonin: 0.107±0.042 ng/ml; C-reactive protein: 23±5.5 mg/dl). Two Crohn&#8217;s disease patients had procalcitonin value above 1 ng/ml. Receiver operating characteristic curve analysis demonstrated that C-reactive protein is the best marker of disease activity in inflammatory bowel disease while procalcitonin has low sensitivity and specificity. Serum procalcitonin levels were highly correlated with serum C-reactive protein but no other disease activity parameters. Conclusions: Although still within normal ranges, procalcitonin levels were slightly elevated in Crohn&#8217;s disease but not in ulcerative colitis patients compared to healthy controls. Serum C-reactive protein is a reliable marker for disease activity in inflammatory bowel disease. Procalcitonin has no diagnostic value in determining disease activity.

Özet

Amaç: Prokalsitonin ve C-reaktif protein akut faz reaktanı olarak davranan iki proteindir. Prokalsitonin bakteriyel enfeksiyonlar için daha spesifik bir gösterge olarak kabul edilmektedir. Bu çalışmada serum prokalsitonin ve C-reaktif protein seviyelerinin inflamatuvar barsak hastalığı aktivitesinin bir göstergesi olarak karşılaştırılması planlanmıştır. Yöntem: İnşamatuvar barsak hastalığı kliniğinde yatarak yeni tanı almış, immunsüpresif ilaç kullanmayan ardışık hastalar çalışmaya dahil edilmiştir. Hastalık aktivitesi, sedimantasyon hızı, C-reaktif protein ve prokalsitonin seviyeleri 45 inşamatuvar barsak (9 Crohn ve 36 ülseratif kolit) hastasında değerlendirilmiştir. Sağlıklı 50 gönüllü kontrol grubu olarak incelenmiştir. Bulgular: Crohn hastalığı olgularında prokalsitonin ve C-reaktif protein sağlıklı kontrollerden daha yüksek bulunmuştur (Prokalsitonin: 0.143±0.081 kfl. 0.065±0.008 ng/ml, p<0.05 ve C-reaktif protein: 29±7.5 kfl. 2.9±0.5 mg/dl, p<0.001). Ülseratif kolit hastalarında prokalsitonin kontrollerden hafif yüksek bulunmuştur ancak fark anlamlı değildir. Creaktif protein ise ülseratif kolitte anlamlı olarak kontrollerden yüksektir. (Prokalsitonin: 0.107±0.042 ng/ml ve C-reaktif protein: 23±5.5 mg/dl). İki Crohn hastalığı olgusunda prokalsitonin değeri 1 ng/ml üzerinde saptanmıştır. Serum prokalsitonin, C-reaktif protein ile koreledir ancak diğer aktivite göstergeleri ile korelasyonu yoktur. Sonuçlar: Serum prokalsitonin seviyesi normal sınırlarda olmakla birlikte, Crohn hastaları nda kontrolerden hafif yüksektir. Ülseratif kolit hastalarında ise prokalsitonin seviyesi sağlıklı kontrollerden farklı değildir. Serum C-reaktif protein seviyesi inşamatuvar barsak hastalığında aktivitenin güvenilir bir göstergesidir ancak prokalsitoninin aktivite göstergesi olarak değeri yoktur.

🔖

Cite This Article

ORUÇ, N., ÖZÜTEMİZ, A. Ö., OSMANOĞLU, N., İLTER, T. (2009). İnflamatuvar barsak hastalığı aktivitesinin belirlenmesinde serum prokalsitonin seviyesinin önemi. Turkish Journal of Gastroenterology, Cilt: 20 - Sayı: 1, 9–12. https://ajindex.com/articles/410845

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Torres MI, Rios A. Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. World J Gastroenterol 2008; 14: 1972-80
  2. Papp M, Norman GL, Altorjay I, Lakatos PL. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol 2007; 13: 2028-36
  3. Desai D, Faubion WA, Sandborn WJ. Biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007; 25: 247-55
  4. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54
  5. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55: 426-31
  6. Le Moullec JM, Jullienne A, Chenais J, et al. The complete sequence of human preprocalcitonin. FEBS Lett 1984; 167: 93-7
  7. Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39: 206-17
  8. Eberhard OK, Haubitz M, Brunkhorst FM, et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/ systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997; 40: 1250-6
  9. Moosig F, Csernok E, Reinhold-Keller E, et al. Elevated procalcitonin levels in active Wegener's granulomatosis. J Rheumatol 1998; 25: 1531-3
  10. Podolsky K. Inflammatory bowel disease. N Engl J Med 1991; 325: 928-37
  11. Best WR, Becktel JM, Singleton JW, Kern FJ. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44
  12. Truelove SC, Witts LJ. Cortisone in the treatment of ulcerative colitis. Final report of a therapeutic trial. Br Med J 1955; 2: 1041-8
  13. Linskens RK, van Bodegraven AA, Schoorl M, et al. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci 2001; 46: 644-8
  14. Muller CA, Uhl W, Printzen G, et al. Role of procalcitonin and granulocyte colony stimulating factor in the early prediction of infected necrosis in severe acute pancreatitis. Gut 2000; 46: 233-8
  15. Ammori BJ, Becker KL, Kite P, et al. Calcitonin precursors: early markers of gut barrier dysfunction in patients with acute pancreatitis. Pancreas 2003; 27: 239-43
  16. Sarbinowski R, Arvidsson S, Tylman M, et al. Plas